Manish Jha, MD, MBBS

Surveys preclinical and emerging clinical evidence for GLP-1 receptor agonists as candidate treatments for alcohol and other substance use disorders.

Alcohol Use DisorderGLP-1 & Metabolic PsychiatrySubstance Use Disorders

Reviews current and investigational neuromodulation techniques for substance use disorders, including rTMS and focused ultrasound.

Neuromodulation (ECT, TMS)Drug Pipeline & Clinical TrialsSubstance Use Disorders

November 12, 2026, 09:00–10:40

Reviews preclinical, observational and early randomized trial evidence on using GLP-1 receptor agonists to treat alcohol and other substance use disorders, including psychiatric safety.

Alcohol Use DisorderGLP-1 & Metabolic PsychiatrySubstance Use Disorders

November 13, 2026, 09:00–10:40

Examines current and emerging neuromodulation approaches such as rTMS and focused ultrasound for treating substance use disorders, including personalization and response monitoring.

Neuromodulation (ECT, TMS)Drug Pipeline & Clinical TrialsSubstance Use Disorders

October 30, 2026, 10:30–12:30

Poster relating wearable-measured sleep and heart rate variability to anxiety in pregnant and postpartum youth with PTSD.

Anxiety DisordersPerinatal & Women's Mental HealthPTSD & TraumaSleep & Insomnia

September 17, 2026

Helps clinicians decide between pharmacotherapy and CBT, mindfulness, sleep, and exercise strategies at the outset of GAD treatment based on severity, comorbidity, trauma history, and preference.

Anxiety DisordersLifestyle & Integrative PsychiatryPsychotherapy

September 17, 2026

Step-by-step framework for treatment-resistant anxiety after SSRI/SNRI failure, covering sequencing, psychotherapy integration, and off-label and emerging agents from gabapentinoids to glutamatergic and GABAergic options.

Anxiety DisordersDrug Pipeline & Clinical TrialsPsychotherapy